Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.

Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF.

Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-189-94.


Mortality trends of HIV-infected patients after the introduction of highly active antiretroviral therapy: analysis of a cohort of 3,322 HIV-infected persons.

Mayor AM, Gómez MA, Ríos-Oliveras E, Hunter-Mellado RF.

Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-57-62.


Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.


The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico.

Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S.

Medicine (Baltimore). 2003 Jan;82(1):39-50.


Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.

Rubaihayo J, Tumwesigye NM, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F.

BMC Res Notes. 2016 Dec 7;9(1):501.


Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.


Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, Costagliola D, Salmon D, Chêne G, Morlat P.

Cancer. 2004 Jul 15;101(2):317-24.


Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.

Cobucci RN, Lima PH, de Souza PC, Costa VV, Cornetta Mda C, Fernandes JV, Gonçalves AK.

J Infect Public Health. 2015 Jan-Feb;8(1):1-10. doi: 10.1016/j.jiph.2014.08.003. Epub 2014 Oct 5. Review.


[Changes in the spectrum of morbidity and mortality in hospital admissions of HIV infected patients during the HAART era].

Escolano Hortelano CM, Ramos Rincón JM, Gutiérrez Rodero F, Masiá Canuto M, Hernández Aguado I, Benito Santaleocadia C, Padilla Urrea S, Martín-Hidalgo A.

Med Clin (Barc). 2004 Jan 17;122(1):1-5. Spanish.


Cancer incidence and all-cause mortality in HIV-positive patients in Northeastern Algeria before and during the era of highly active antiretroviral therapy.

Chaabna K, Newton R, Vanhems P, Laouar M, Forman D, Boudiaf Z, Soerjomataram I.

J Cancer Res Ther. 2016 Apr-Jun;12(2):576-81. doi: 10.4103/0973-1482.179521.


Cancer in HIV-infected persons from the Caribbean, Central and South America.

Fink VI, Shepherd BE, Cesar C, Krolewiecki A, Wehbe F, Cortés CP, Crabtree-Ramírez B, Padgett D, Shafaee M, Schechter M, Gotuzzo E, Bacon M, McGowan C, Cahn P, Masys D; Caribbean Central South America Network for HIV Research Collaboration of the International Epidemiologic Databases to Evaluate AIDS Program.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):467-73. doi: 10.1097/QAI.0b013e31820bb1c3.


Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.

Martínez E, Milinkovic A, Buira E, de Lazzari E, León A, Larrousse M, Loncá M, Laguno M, Blanco JL, Mallolas J, García F, Miró JM, Gatell JM.

HIV Med. 2007 May;8(4):251-8.


Noninfectious pulmonary complications of HIV/AIDS.

Kanmogne GD.

Curr Opin Pulm Med. 2005 May;11(3):208-12. Review.


Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G; Mortality 2000 study group.

Int J Epidemiol. 2005 Feb;34(1):121-30. Epub 2004 Nov 23.


Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.

Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, Hung CC, Yang SY.

HIV Med. 2008 Aug;9(7):535-43. doi: 10.1111/j.1468-1293.2008.00600.x. Epub 2008 Jun 28.


Malignancies in HIV: pre- and post-highly active antiretroviral therapy.

Nutankalva L, Wutoh AK, McNeil J, Frederick WR, Reddy RB, Daftary M, Gentles A, Addae-Afoakwa K.

J Natl Med Assoc. 2008 Jul;100(7):817-20.


Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART).

Mayor AM, Fernández Santos DM, Dworkin MS, Ríos-Olivares E, Hunter-Mellado RF.

Am J Trop Med Hyg. 2011 May;84(5):838-41. doi: 10.4269/ajtmh.2011.10-0718.


Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India.

Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Yephthomi T, Pradeep A, Saghayam S, Flanigan T, Mayer KH, Solomon S.

Int J Infect Dis. 2010 Feb;14(2):e127-31. doi: 10.1016/j.ijid.2009.03.034. Epub 2009 Jul 25.

Supplemental Content

Support Center